[Treatment of Paget's disease with diphosphonate (disodium ethydronate)].
16 patients suffering from Paget's disease were studied before, during and after 3 or 6 month treatment with disodium ethydronate (EHDP) per os. An appreciable improvement in pain symptomatology was noted and at times an evident improvement in audiometry; from the metabolic viewpoint there was a fall in serum alkaline phosphatase and urinary excretion of calcium and hydroxyproline. A study of radiocalcium kinetics demonstrated a reduction in the exchangeable calcium pool and the fractional turnover rate. Histological examination following needle biopsy of the iliac crest showed evident diminution in the active bone cell population (osteoclasts, osteoblasts) and, in certain cases, appearance of osteoid borders.
D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000473:pathology; D002118:Calcium / Q000652:urine; D012968:Etidronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000473:pathology
D009943:Organophosphorus Compounds; D000469:Alkaline Phosphatase; D012968:Etidronic Acid; D006909:Hydroxyproline; D002118:Calcium
Terapia del morbo di paget con difosfonato (disodio etidronato)